Sherry Clounch
Acute Care · Athens, ALNPI 1538617741
Payments from drug & device makers
Across 35 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$167
- Amgen$68
- Merck$55
- Boston Scientific$41
- Xeris Pharmaceuticals, Inc.$40
- GSK$37
- plus $182 from 10 others
What the payments were for
- Food & beverage$590100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 8 | $167 |
| Amgen | 4 | $68 |
| Merck | 4 | $55 |
| Boston Scientific | 3 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| GSK | 3 | $37 |
| Novo Nordisk | 2 | $37 |
| Dexcom, Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Tolmar, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Medtronic | 1 | $12 |
| Pfizer | 1 | $12 |
How this compares
$590 in reported general payments places this provider in the 55th percentile of 711 acute care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 11 | $262 |
| Cefdinir | 13 | $219 |
| Levothyroxine Sodium | 12 | $142 |
| Levocetirizine Dihydrochloride | 11 | $129 |
| Cyclobenzaprine Hcl | 11 | $102 |
| Metformin Hcl | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Other acute care in Athens
- Paige HarrisMontgomery$465K
- Coretta CollinsBirmingham$77K
- Debra DavisFoley$31K
- Leslie GastonMobile$22K
- Gwendolyn HooperTuscaloosa$16K
- Rachel PrytulaDothan$14K
- Jennifer UmbargerMobile$14K
- April KlarHuntsville$13K
- Cameron StephensonBirmingham$13K
- Jonathan McCraryBirmingham$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.